-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections
(2332) Views (520) Full article downloads
Authors: Mary L Townsend, Melanie W Pound, Richard H Drew
Published Date January 2007
Volume 2007:3(6) Pages 1059 - 1070
DOI: http://dx.doi.org/10.2147/TCRM.S
Mary L Townsend1, Melanie W Pound1, Richard H Drew1,2,3
1Campbell University School of Pharmacy, Buies Creek, NC, USA; 2Duke University Medical Center, Durham, NC, USA; 3Duke University School of Medicine, Durham, NC, USA
Abstract: Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new option for the treatment of complicated intra-abdominal and complicated skin and skin structure infections. It displays favorable activity in vitro against the most common causative Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered intravenously twice daily has demonstrated efficacy similar to comparators for a variety of complicated skin and skin structure and complicated intra-abdominal infections. The potential for significant drug interactions with tigecycline appears to be minimal. Dosing adjustment is needed for patients with severe hepatic impairment. The predominant side effect associated with its use to date has been gastrointestinal intolerance (nausea and vomiting).
Keywords: tigecycline, intra-abdominal infections, complicated skin and skin structure infections
Readers of this article also read:
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Jet lag syndrome: circadian organization, pathophysiology, and management strategies
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Corrigendum
Erratum
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




